STOCK TITAN

Redhill Biopharma Ltd. - RDHL STOCK NEWS

Welcome to our dedicated page for Redhill Biopharma Ltd. news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharma Ltd. stock.

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company centered on gastrointestinal and infectious diseases. The company is headquartered in Israel and operates internationally, with teams in the U.S., Canada, and Europe. RedHill's primary focus is the development and commercialization of late-stage clinical therapeutics and patented reformulations of existing drugs.

Core Business and Products

RedHill's flagship commercial products in the U.S. include Talicia® (omeprazole, amoxicillin, and rifabutin) for treating Helicobacter pylori (H. pylori) infection in adults, and Aemcolo® (rifamycin) for treating travelers' diarrhea. Talicia® is unique as the only FDA-approved rifabutin-containing therapy optimized for H. pylori eradication, addressing the rising concern of antibiotic resistance.

Key Development Programs

  • Opaganib (ABC294640): A first-in-class oral SPHK2 inhibitor with applications in pandemic preparedness, oncology, and radioprotection. It is undergoing trials for multiple indications including Acute Radiation Syndrome (ARS) and COVID-19, and has shown promising results in pre-clinical studies against Ebola.
  • RHB-107 (upamostat): An oral broad-acting, host-directed serine protease inhibitor targeting non-hospitalized symptomatic COVID-19, supported by U.S. Department of Defense funding in a 300-patient Phase 2 trial. It also shows potential for cancer and inflammatory gastrointestinal diseases.
  • RHB-102: A novel therapy for chemotherapy and radiotherapy-induced nausea and vomiting, with positive Phase 3 results for acute gastroenteritis.
  • RHB-104: Demonstrated efficacy in a Phase 3 study for Crohn's disease.
  • RHB-204: In Phase 3 development for pulmonary nontuberculous mycobacteria (NTM) disease.

Recent Achievements

Recent publications highlight Opaganib's efficacy in enhancing long-term survival in radiation exposure models, and its selection by the U.S. NIH for the Radiation and Nuclear Countermeasures Program. Additionally, the company secured a new U.S. patent for Talicia®, extending its protection until 2034, and obtained a new Chinese patent for Opaganib in combination with immune checkpoint inhibitors, valid through 2040.

Financial Performance

For the year ending December 31, 2023, RedHill reported net revenues of $6.5 million, primarily from Talicia®, with a gross profit of $3.1 million. The company has reduced its liabilities significantly following the divestiture of Movantik, and its financial health is bolstered by ongoing U.S. government funding for key R&D programs.

Strategic Direction

RedHill is focused on leveraging its solid pipeline and partnerships to address unmet medical needs in gastrointestinal and infectious diseases. The company is strategically positioned to benefit from growing geopolitical and health threats, aiming to provide innovative solutions in challenging healthcare environments.

Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) announced that Movantik® (naloxegol) has been added as an unrestricted preferred brand to a major national commercial formulary, effective July 1, 2021. This inclusion means over 30 million more Americans will gain access to Movantik, which treats opioid-induced constipation. Nearly 90% of U.S. commercial lives are now covered. Movantik's effectiveness and importance for pain management are emphasized, with ongoing efforts to expand formularies further. The safety information highlights potential gastrointestinal risks associated with Movantik usage.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.11%
Tags
none
-
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) announced preliminary results from a preclinical study showing that opaganib effectively inhibits the Beta and Gamma COVID-19 variants. This investigational oral drug targets sphingosine kinase-2 (SK2), crucial for viral replication. The global Phase 2/3 study of opaganib, fully enrolled with 475 patients, is nearing completion, with encouraging preliminary safety and efficacy data. Opaganib's dual mechanism combines antiviral and anti-inflammatory effects, showing potential against emerging COVID-19 variants.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
clinical trial covid-19
-
Rhea-AI Summary

RedHill Biopharma (RDHL) announced positive Phase 2 data for oral opaganib (Yeliva®) in hospitalized COVID-19 patients at the World Microbe Forum. In a 40-patient study, 50% of opaganib recipients reached room air by Day 14, compared to 22% for placebo. Additionally, 86.4% of opaganib patients were discharged by Day 14 versus 55.6% for placebo. Median discharge time was 6 days for opaganib versus 7.5 days for placebo. No significant safety issues were noted. Following the completion of a 475-patient global Phase 2/3 study, further data is expected soon.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
clinical trial covid-19
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) announced that Adi Frish, Chief Corporate & Business Development Officer, will present a corporate overview at the BIO Digital International Convention from June 14-18, 2021. The presentation will be accessible on the company’s website for 30 days post-conference. RedHill specializes in treatments for gastrointestinal and infectious diseases, including Movantik®, Talicia®, and Aemcolo®. Key clinical programs include RHB-204 for pulmonary NTM disease and others targeting COVID-19 and cancers. More at redhillbio.com.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
conferences
-
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) announced the completion of patient enrollment in its global Phase 2/3 study of opaganib (Yeliva®, ABC294640) for treating severe COVID-19 pneumonia, exceeding its target with 475 randomized patients. The study's primary endpoint aims to assess the proportion of patients breathing independently by Day 14. Preliminary data suggests encouraging intubation and mortality rates compared to larger studies. Ongoing discussions with regulatory authorities and potential partners are underway to evaluate the next steps for opaganib's market introduction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
clinical trial covid-19
-
Rhea-AI Summary

RedHill Biopharma reported Q1 2021 financial results with net revenues of approximately $20.6 million, down $0.9 million from Q4 2020. Gross profit decreased slightly to $10.3 million, maintaining a 50% gross margin. R&D expenses rose to $7.5 million due to COVID-19 programs. Operating loss was $18.2 million, while net loss totaled $22.9 million. Cash balance stood at $92.1 million. The company highlighted progress in COVID-19 programs with Opaganib nearly fully enrolled in a Phase 2/3 study.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) announced receipt of two Notices of Allowance from the USPTO for patents covering its COVID-19 treatments, opaganib and RHB-107, extending protection until at least 2041. Both oral therapies target viral replication and are expected to be effective against emerging variants. Recruitment for opaganib's Phase 2/3 study is nearly complete, while RHB-107's study is ongoing. The company is assessing regulatory paths for opaganib, focusing on countries severely affected by COVID-19, pending positive study data. The strength of safety and efficacy data is crucial for regulatory submissions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.38%
Tags
covid-19
-
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) presented new analyses of Movantik® at Digestive Disease Week 2021, showcasing its rapid onset and sustained efficacy in treating opioid-induced constipation (OIC). The studies pooled data from 891 patients, indicating significant symptom relief compared to 546 in placebo groups. Prof. William D. Chey highlighted the importance of early relief for OIC sufferers, which affects 40-80% of chronic opioid users. Movantik is crucial for pain management, countering one of the main side effects of opioid therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.84%
Tags
none
-
Rhea-AI Summary

RedHill Biopharma (Nasdaq: RDHL) presented a new Travelers' Diarrhea (TD) severity classification tool at Digestive Disease Week 2021, developed with the University of Texas School of Public Health. This tool aims to enhance clinical practice by providing clear separation of TD severity categories. The efficacy of Aemcolo (rifamycin) was confirmed through this tool, showing high effectiveness in moderate to severe TD cases. Aemcolo is noteworthy for its non-systemic delivery, resulting in limited side effects. This advancement could boost demand as travel resumes post-COVID.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
none
Rhea-AI Summary

RedHill Biopharma Ltd. (Nasdaq: RDHL) will announce its first quarter 2021 financial results and operational highlights on May 27, 2021. A live webcast is scheduled for 8:30 a.m. EDT on the same day, allowing stakeholders to access key information, including performance metrics. RedHill focuses on gastrointestinal and infectious diseases, with products like Movantik, Talicia, and Aemcolo. Its ongoing clinical programs include RHB-204 for pulmonary NTM disease and opaganib for COVID-19 treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
conferences earnings

FAQ

What is the current stock price of Redhill Biopharma Ltd. (RDHL)?

The current stock price of Redhill Biopharma Ltd. (RDHL) is $6.5 as of December 20, 2024.

What is the market cap of Redhill Biopharma Ltd. (RDHL)?

The market cap of Redhill Biopharma Ltd. (RDHL) is approximately 8.1M.

What does RedHill Biopharma Ltd. specialize in?

RedHill Biopharma specializes in the development and commercialization of therapeutics for gastrointestinal and infectious diseases.

What are RedHill's main commercial products?

RedHill's main commercial products are Talicia® for Helicobacter pylori infection and Aemcolo® for travelers' diarrhea.

What is Opaganib, and what are its potential uses?

Opaganib is an investigational drug targeting SPHK2 with potential uses in pandemic preparedness, oncology, and radioprotection.

What stage is RHB-107 currently in?

RHB-107 is in late-stage development, specifically a 300-patient Phase 2 adaptive platform trial for non-hospitalized symptomatic COVID-19.

What recent achievements has RedHill Biopharma accomplished?

Recent achievements include new patents for Talicia® and Opaganib and successful pre-clinical study results for Opaganib's use against Ebola and radiation exposure.

How is RedHill Biopharma's financial performance?

For the year ending December 31, 2023, RedHill reported net revenues of $6.5 million and a gross profit of $3.1 million, with a significant reduction in liabilities.

What is the strategic direction of RedHill Biopharma?

RedHill is focusing on leveraging its robust pipeline and strategic partnerships to address unmet medical needs in gastrointestinal and infectious diseases.

Who are RedHill Biopharma's development partners?

RedHill collaborates with various entities including the U.S. National Institutes of Health and the U.S. Department of Defense for its development programs.

What is the significance of RedHill's new patents?

The new patents enhance RedHill's intellectual property portfolio, providing extended protection for its key products and potential new treatments.

Where can more information about RedHill Biopharma be found?

More information can be found on the company's website at www.redhillbio.com and their Twitter page at twitter.com/RedHillBio.

Redhill Biopharma Ltd.

Nasdaq:RDHL

RDHL Rankings

RDHL Stock Data

8.08M
1.28M
5.9%
0.53%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Tel Aviv